Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib
Source : https://insight.jci.org/articles/view/160909
Recent clinical trials show promising results for the next-generation Bruton's tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B cells. Whether and how BTK activity shapes B cells as key drivers of MS is currently unclear.
Conclusion/Relevance: These findings demonstrate a functional link between BTK activity and disease-relevant B cells and offer valuable insights into how next-generation BTK inhibitors could modulate the clinical course in MS patients.